四聚体法定量分析EBV相关鼻咽癌患者外周血特异性CTL

Quantitative analysis of specific CTL in patients with EBV-associated nasopharyngeal carcinoma

目的探讨鼻咽癌(NPC)患者对Epstein-Barr病毒(EBV)潜伏膜蛋白(LMP)1、2的细胞免疫应答。方法采用人类白细胞抗原(HLA)-肽四聚体法检测14例NPC患者(NPC组)及10例EBV阳性无症状者(对照组)外周血8个LMP1、LMP2表位特异性细胞毒性T淋巴细胞(CTL)频率。结果 NPC组ALL、FLY、LLW表位特异性CTL频数分别为(0.25±0.14)%、(0.28±0.22)%、(0.26±0.19)%,低于对照组的(0.45±0.20)%、(1.03±0.63)%、(0.64±0.35)%(P<0.05),其余5个表位特异性CTL频数组间比较无统计学差异(P>0.05)。结论与EBV阳性无症状者比较,NPC患者对ALL、FLY、LLW的特异性免疫应答能力减弱,相应表位特异性CTL或许也可用于NPC免疫治疗。

Objective To evaluate the immune response to latent membrane protein（LMP）1 and 2 in patients with Epstein-Barr virus（EBV）-associated nasopharyngeal carcinoma（NPC）.Methods Human leucocyte antigen（HLA）-peptide tetramers were used for the detection of 8 kinds epitope-specific cytotoxic T lymphocyte in peripheral blood of 14 patients with NPC（NPC group） and 10 healthy EBV carriers.Results The mean percentages of ALL,FLY and LLW tetramer positive CTL were（0.25±0.14）%,（0.28±0.22）% and（0.26±0.19）% in NPC group,which were lower than（0.45±0.20）%,（1.03±0.63）% and（0.64±0.35）%（P0.05）.Conclusion Patients with NPC might demonstrate a weaker response to several epitopes of LMP1 and LMP2 than healthy control.Expansion these epitope-specific CTL could offer a viable immunotherapy for NPC patients.